TITLE

Heterogeneity: Cooperative crosstalk

AUTHOR(S)
Seton-Rogers, Sarah
PUB. DATE
April 2015
SOURCE
Nature Reviews Cancer;Apr2015, Vol. 15 Issue 4, p198
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the study "Intratumoral Heterogeneity in a p53 Null Mouse Model of Human Breast Cancer" by researcher M. Zhang and colleagues and published win the journal "Cancer Discovery" which discusses factors promoting tumour growth in breast.
ACCESSION #
101720506

 

Related Articles

  • Loss of p53-immunostaining intensity in breast cancer. Henson, Donald E. // JNCI: Journal of the National Cancer Institute;08/07/96, Vol. 88 Issue 15, p1015 

    Editorial. Comments on the impact of lost immunostaining intensity of the P53 antioncogene in treating breast cancer. Amount of immunoreactivity lost after two weeks storage on unstained glass slides; Chemicals and stain preparation procedures suspected for the lost immunostaining capacity of...

  • Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. Jacobs, Timothy W.; Prioleau, John E. // JNCI: Journal of the National Cancer Institute;08/07/96, Vol. 88 Issue 15, p1054 

    Discusses the decrease in the immunostaining properties of the P53 antioncogenes in slides of breast cancer samples. Theories linking environmental storage conditions and slide preparation chemicals to immunostaining loss; Progress of the decline in staining intensity after two weeks.

  • Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Regele, S; Kohlberger, P; Vogl, F D; Böhm, W; Kreienberg, R; Runnebaum, I B // British Journal of Cancer;10/15/99, Vol. 81 Issue 4, p702 

    Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of ≤ 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological...

  • Pathology/cytology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS75 

    Presents an abstract of the research manuscript `P53, ErbB2 and TAG-72 expression in the spectrum of ductal carcinoma in situ of the breast classified by the Van Nuy's System,' by R. Kanthan et al.

  • Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Somlo, G.; Simpson, J.F.; Frankel, P.; Chow, W.; Leong, L.; Margolin, K.; Jr., R. Morgan; Raschko, J.; Shibata, S.; Forman, S.; Kogut, N.; McNamara, M.; Molina, A.; Somlo, E.; Doroshow, J.H. // British Journal of Cancer;7/29/2002, Vol. 87 Issue 3, p281 

    Identifies the predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Survival rate; p53 protein expression; Estrogen-progesterone receptor status; Stage of the disease; Mitotic index.

  • Assessing p53 status in breast cancer prognosis: Where should you put the thermometer if you... Elledge, Richard M. // JNCI: Journal of the National Cancer Institute;2/21/96, Vol. 88 Issue 3/4, p141 

    Focuses on the assessment of p53 gene status in breast cancer prognosis. Differences in assay techniques; Inactivation of the p53 protein; Sequencing of the entire coding region.

  • Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Gentile, Massimiliano; Ahnström, Marie; Schön, Fredrik; Wingren, Sten // Oncogene;11/22/2001, Vol. 20 Issue 53, p7753 

    One of the most consistently deleted chromosomal regions in solid tumours is 11q23–q25, which consequently has been postulated to harbour one or more tumour suppressor loci. Despite large efforts to identify the responsible genes, the goal remains elusive, but as knowledge accumulates new...

  • BRCA1 activation of the GADD45 promoter. Jin, Shunqian; Zhao, Hongcheng; Fan, Feiyue; Blanck, Patricia; Fan, Wenhong; Colchagie, Amy B; Fornace, Albert J; Zhan, Qimin // Oncogene;8/17/2000, Vol. 19 Issue 35, p4050 

    Breast cancer susceptibility gene BRCA1 has been implicated in the control of gene regulation and such regulated genes are thought to mediate the biological role of BRCA1. Overexpression of BRCA1 induces GADD45, a p53-regulated and stress-inducible gene. However, the molecular mechanism by which...

  • p21WAF1/CIP1 response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Guillot, Céline; Falette, Nicole; Paperin, Marie-Pierre; Courtois, Stéphanie; Gentil-Perret, Anne; Treilleux, Isabelle; Ozturk, Mehmet; Puisieux, Alain // Oncogene;1/9/97, Vol. 14 Issue 1, p45 

    Functional inactivation of the wild-type p53 protein has been described in different human cancers. Since a significant proportion of breast tumours express wild-type TP53, the p53 antiproliferative activity could be inactivated in transformed mammary epithelial cells by a mechanism independent...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics